The DOI matches its Crossref record.
Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Abstract
OBJECTIVE: Psychotropic drugs often induce weight gain, leading to discomfort and discontinuation of treatment and, more importantly, increasing the risk of obesity-related illnesses such as diabetes mellitus, hypertension, and coronary heart disease. There is evidence that antidepressant drugs may induce a variable amount of weight gain, but results are sparse and often contradictory. DATA SOURCES: We performed a literature search using the MEDLINE, ISI Web of Knowledge, and Cochrane research databases for all publications available to January 2009. We used the following keywords: antidepressant, psychotropic drugs, body weight, weight gain, obesity, overweight, adverse event, side effects, SSRIs, tricyclic antidepressants, and the name of each antidepressant active compound together with body weight or other keywords. Studies reporting body weight changes during treatment with different antidepressants were selected for eligibility. Finally, 116 studies were included in the analysis. DATA EXTRACTION: Weight change mean and standard deviation and size of each group were recorded. Missing means and standard deviations were directly calculated by using information available in the article when possible. Non-placebo-controlled studies were compared to a virtual placebo sample, whose mean and standard deviation were derived by the weighted mean of means and standard deviations of all placebo samples. Methodological quality of studies, heterogeneity, publication bias, and effect of treatment duration were systematically controlled. DATA SYNTHESIS: Quantitative results evidenced that amitriptyline, mirtazapine, and paroxetine were associated with a greater risk of weight gain. In contrast, some weight loss occurs with fluoxetine and bupropion, although the effect of fluoxetine appears to be limited to the acute phase of treatment. Other compounds have no transient or negligible effect on body weight in the short term. However, the effect of each antidepressant may vary greatly depending on an individual's characteristics and generally became more evident in the long term to a variable degree across compounds. CONCLUSIONS: Despite the fact that some analyses were done on only a few studies due to the difficulty of finding reliable information in literature, to our knowledge, this is the first comprehensive meta-analysis to allow comparison of different antidepressants as regards their impact on body weight. Data presented may be helpful for a more accurate treatment selection in patients at risk of obesity or related medical illness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the persistence of some residual symptoms (e.g., cognitive and sleep disturbances)”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [5]
In the citing paper
“The sedative antidepressants may also induce a weight gain, what is particularly shown for mirtazapine but not for trazodone [23].”
From Effects of Antidepressants on Sleep (2017) · cites this paper as [23]
In the citing paper
“Amitriptyline and mirtazapine consistently showed weight gaining effects throughout acute and long-term treatment.”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [70]
In the citing paper
“A meta-analysis further showed that SSRIs including citalopram, escitalopram, fluoxetine, sertraline, paroxetine and SNRIs including venlafaxine and duloxetine were associated with weight loss compared with placebo.”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [70]
In the citing paper
“Imipramine and bupropion showed significant weight loss effects for both acute and long term treatment (Table 5).70”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [70]
Citations
Cited by
Sorted by citations
Items 601–622 of 622
Tsang, L., & Weezep, J. V. (2026) · Evidence-Based Practice · doi:10.1097/ebp.0000000000002596
Xie, Y., Jin, J., & Zhou, T. (2026) · Medicine · doi:10.1097/md.0000000000048900
“[6,29] These factors can significantly dilute or mask the predictive power of cardiometabolic indices on over-all mortality.”
Yan, H., Huang, W., Xia, H., et al. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s601238
“…reported in healthy subjects (eg., 42 L/h) 1 , this finding is consistent with the characteristics of the Chinese population (associated with a higher concentration-to-dose ratio in Asians) 10 and real-world clinical patients (including the elderly and those with varying physiological states).”
Reizer, B., Białek, J. B., Dusiłło, W., & Kruk, J. K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4593
Vortioxetine transiently alters basal locomotor activity but does not produce sedation in rats
Barbosa-Méndez, S., & Salazar‐Juárez, A. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115412
Genetic perspectives on the comorbidity of anxiety and mood disorders with cardiovascular disease
de Geus, E. J. C., Treur, J. L., & Penninx, B. W. J. H. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00822-6 · Cited by 1
“However, as this analysis was not restricted to randomized”
Zuber, J., Thomas, M. L., Stein, M. B., & Meruelo, A. D. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02342-7
“Antidepressant medications may further contribute to metabolic dysregulation, particularly through weight gain and insulin resistance [8].”
Kleinerman, A., Benrimoh, D. A., Yaniv‐Rosenfeld, A., Golden, G. M., Tanguay-Sela, M., Margolese, H. C., Lazebnik, T., Amit, B. H., Samuel, H., & Rosenfeld, A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1851899
Maric, E., Wang, C., Zukancic, S., Kuchta, K., Amundson, J. R., Rolnik, A., Hedberg, H. M., Linn, J. G., Denham, E. W., Ujiki, M., et al. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-12943-x
“Certain classes of antidepressants are associated with weight gain, while others are weight-neutral or associated with modest weight loss [7].”
Skobeleva, T. N., Savgacheva, M. Y., & Karakchiev, D. A. (2026) · Patient-Oriented Medicine and Pharmacy · doi:10.37489/2949-1924-0139
Serretti, A. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111854
Self-citationNeuroinflammation as a Key Target in the Treatment of Post-Stroke Depression
Bender, T. B., & Bykov, Y. N. (2026) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-026-02030-y
“Fluvoxamine has a favorable tolerability pro fi le: a low incidence of insomnia, a minimal risk of agitation at the beginning of therapy, minor effects on the QT interval and body weight, as well as a relatively low incidence of sexual dysfunction and withdrawal syndrome [69–71].”
Cheung, N., Cheung, H. K., Yu, Y. W., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10656343/v1
Corrado, R., Raffa, S. D., Bauer, E. M., Eisenberg, D., Weare-Regales, N., Antonovich, N., Loblack, A., Berdiel, E., Kelber, M. S., Klimovich, J., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00676
Liu, D., Baranova, A., Xu, C., Sun, W., Cao, H., & Zhang, F. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02369-w
Huang, S., Wu, F., Zhong, L., Li, H., Zhang, Z., He, Y., Wu, J., Chen, B., Zheng, J., & Huang, Y. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122465
Neuroinflammation as a Key Target in the Treatment of Post-Stroke Depression
Bender, T. B., & Bykov, Y. (2026) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-026-02063-3
“…fl uvoxamine has a favorable tolerability pro fi le: a low incidence of insomnia, minimal risk of developing agitation at the beginning of therapy, and minor effects on the QT interval and body weight, as well as a relatively low incidence of sexual dysfunction and withdrawal syndrome [69–71].”
RNA m6A demethylase FTO in central nervous system disorders: Mechanisms and therapeutic implications
Bi, H., Sun, M., Ma, Q., Li, X., & Wang, Y. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111942
李红涛, Yin, T., Wang, Y., Wang, Y., Xu, N., Yi, W., & Yang, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1978249
Drugs for Weight Loss and Maintenance: Present and Future
Pasarica, M., & Smith, S. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1203-2_16
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
Prevention of Depression in Medical Conditions
Dong, L., & Gallo, J. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-16045-0_4
Metadata
- Authors
- Serretti, A., & Mandelli, L.
- Affiliations
- University of Bologna (IT)
- Corresponding author
- Serretti, Alessandro
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-10-15
- Volume
- 71
- Issue
- 10
- Pages
- 1259-1272
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2030270520
- Cited by
- 621
- References
- 0
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 46 · 2023: 41 · 2022: 42 · 2021: 41 · 2020: 33 · 2019: 36 · 2018: 37 · 2017: 36 · 2016: 31 · 2015: 47 · 2014: 40 · 2013: 49 · 2012: 41
- FWCI
- 25.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- antidepressants, weight gain, body weight, psychotropic drugs, obesity, amitriptyline, mirtazapine, paroxetine, fluoxetine, bupropion, tricyclic antidepressants, selective serotonin reuptake inhibitors, adverse drug reactions, treatment discontinuation
- MeSH terms
- Antidepressive Agents, Body Weight, Clinical Trials as Topic, Humans, Time Factors, Weight Gain, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review